프리온병 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별(인간 프리온병, 동물 프리온병), 약제별(항우울제, 항정신병제), 지역별, 경쟁별(2020-2030년)
Prion Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity & Forecast Segmented By Type (Human Prion Diseases, Animal Prion Diseases), By Drug (Antidepressant, Antipsychotic Agents), By Region and Competition, 2020-2030F
세계 프리온병 치료 시장은 2024년 49억 7,000만 달러로 평가되며, 예측 기간 동안 CAGR 4.49%로 성장하여 2030년까지 64억 7,000만 달러에 달할 것으로 예상됩니다.
프리온 질환, 즉 전염성 해면상뇌증(TSEs)은 뇌에 잘못 접힌 프리온 단백질이 비정상적으로 축적되어 발생하는 희귀하고 치명적인 신경 퇴행성 질환입니다. 크로이츠펠트 야콥병(CJD), 변종 CJD(vCJD), 치명적인 가족성 불면증(FFI) 등이 이에 해당합니다. 시장 개척은 질병에 대한 인식 제고, 진단법 개선, 효과적인 치료법 개발을 위한 연구개발 활성화 등에 힘입어 꾸준히 확대되고 있습니다. 치료법은 존재하지 않지만, 현재 치료 접근법은 증상 관리와 환자의 삶의 질에 중점을 둔 지지적 치료법입니다. 인간 프리온병은 높은 유병률과 연구 활동으로 인해 주요 부문이 되었습니다. 항우울제는 신경증상 및 정신증상을 관리하는데 중요한 역할을 하기 때문에 주요 약제군으로 자리 잡았습니다. 진단의 복잡성, 낮은 유병률, 제한된 치료 옵션 등의 과제에도 불구하고, 바이오마커 연구, 신경 퇴행성 연구 자금 지원, 첨단 치료법 모색에 대한 혁신은 시장 성장을 더욱 촉진할 것으로 예상됩니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
49억 7,000만 달러 |
| 시장 규모 : 2030년 |
64억 7,000만 달러 |
| CAGR : 2025-2030년 |
4.49% |
| 급성장 부문 |
인간 프리온병 |
| 최대 시장 |
북미 |
시장 촉진요인
프리온병 유병률 증가
주요 시장 과제
프리온병에 대한 제한된 이해
주요 시장 동향
새로운 치료 접근법
- 프리온 복제를 파괴하고 신경독성을 감소시키는 저분자 개발이 진행되고 있습니다.
- 단클론항체는 잘못 접힌 프리온 단백질에 결합하여 중화시킬 가능성이 검토되고 있습니다.
- 안티센스 올리고뉴클레오티드(ASO), RNA 간섭(RNAi) 등 RNA 기반 치료법은 프리온 단백질의 비정상적인 생산을 억제하거나 그 분해를 촉진하는 것을 목적으로 합니다.
- CRISPR-Cas9을 포함한 유전자 치료 기술은 유전성 프리온 질환을 유발하는 유전자 변이 수정에 유망합니다.
이러한 혁신적인 치료법은 대부분 실험 단계에 있지만, 미래의 질병 변형 치료에 희망을 주고 있어 투자와 연구에 대한 관심이 높아지고 있습니다.
목차
제1장 제품 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 프리온병 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 유형별(인간 프리온병, 동물 프리온병)
- 약제별(항우울제, 항정신병제)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 프리온병 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 프리온병 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 프리온병 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 프리온병 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 프리온병 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 프리온병 치료 시장 : SWOT 분석
제14장 경쟁 구도
- Fresenius SE & Co. KGaA
- Elite Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- Novartis AG
- Merck KGaA
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Cipla Ltd
- Teva Pharmaceuticals
- Abbott Laboratories
제15장 전략적 제안
제16장 조사 회사 소개 및 면책사항
ksm
The Global Prion Disease Treatment Market was valued at USD 4.97 Billion in 2024 and is projected to reach USD 6.47 Billion by 2030, growing at a CAGR of 4.49% during the forecast period. Prion diseases, or transmissible spongiform encephalopathies (TSEs), are rare, fatal neurodegenerative disorders resulting from the abnormal accumulation of misfolded prion proteins in the brain. These include conditions such as Creutzfeldt-Jakob Disease (CJD), variant CJD (vCJD), Fatal Familial Insomnia (FFI), and others. The market is witnessing steady expansion, supported by greater disease awareness, improved diagnostics, and increased research initiatives aimed at developing effective therapies. While no cure exists, current treatment approaches are largely supportive, focusing on symptom management and patient quality of life. Human prion diseases are the dominant segment, driven by higher prevalence and research activity. Antidepressants represent the leading drug class due to their role in managing neurological and psychiatric symptoms. Innovations in biomarker research, funding for neurodegenerative studies, and exploration of advanced therapeutic methods are expected to further propel market growth, despite challenges such as diagnostic complexity, low incidence rates, and limited treatment options.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 4.97 Billion |
| Market Size 2030 | USD 6.47 Billion |
| CAGR 2025-2030 | 4.49% |
| Fastest Growing Segment | Human Prior Diseases |
| Largest Market | North America |
Key Market Drivers
Increasing Prevalence of Prion Diseases
The rising incidence of prion diseases globally is a major growth driver for the treatment market. These neurodegenerative disorders, though rare, are increasingly diagnosed due to advancements in medical technology and growing awareness among healthcare professionals. Enhanced diagnostic capabilities have made it possible to identify cases that were previously misdiagnosed or undetected, contributing to a perceived rise in prevalence. Additionally, the aging global population has amplified the incidence of diseases like sporadic CJD, which is more common in older adults. According to the National Library of Medicine, at least 485 cases of iatrogenic CJD (iCJD) have been documented worldwide, most of which occurred prior to 2012. These included cases linked to contaminated surgical tools, EEG needles, corneal transplants, and notably, human-derived growth hormones and dura mater grafts. As detection improves and awareness increases, the demand for prion disease treatments is expected to grow steadily.
Key Market Challenges
Limited Understanding of Prion Diseases
A major challenge hindering the development of effective prion disease therapies is the limited understanding of the diseases' underlying mechanisms. Prion disorders are complex, and their pathogenesis-particularly how prions replicate and cause neurodegeneration-remains only partially understood. This knowledge gap restricts the identification of viable drug targets and slows down therapeutic innovation. The intricacy of prion biology requires extensive research to unravel molecular pathways before advancing drug discovery. This lack of foundational understanding poses a significant barrier to the timely development and approval of effective treatments.
Key Market Trends
Emerging Therapeutic Approaches
Innovative treatment strategies are emerging as key trends in the prion disease treatment landscape. Researchers are investigating a range of novel approaches to halt or reverse disease progression.
- Small molecules are being developed to disrupt prion replication and reduce neurotoxicity.
- Monoclonal antibodies are being explored for their potential to bind and neutralize misfolded prion proteins.
- RNA-based therapies, such as antisense oligonucleotides (ASOs) and RNA interference (RNAi), aim to suppress abnormal prion protein production or promote its breakdown.
- Gene therapy techniques, including CRISPR-Cas9, show promise for correcting genetic mutations responsible for inherited prion disorders.
These therapeutic innovations, though largely in experimental phases, offer hope for disease-modifying treatments in the future and are attracting increasing investment and research attention.
Key Market Players
- Fresenius SE & Co. KGaA
- Elite Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- Novartis AG
- Merck KGaA
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Cipla Ltd
- Teva Pharmaceuticals
- Abbott Laboratories
Report Scope:
In this report, the Global Prion Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Prion Disease Treatment Market, By Type:
- Human Prion Diseases
- Animal Prion Diseases
Prion Disease Treatment Market, By Drug:
- Antidepressant
- Antipsychotic Agents
Prion Disease Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Prion Disease Treatment Market.
Available Customizations:
Global Prion Disease Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Prion Disease Treatment Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Type (Human Prion Diseases, Animal Prion Diseases)
- 5.2.2. By Drug (Antidepressant, Antipsychotic Agents)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
- 5.3. Market Map
6. North America Prion Disease Treatment Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Drug
- 6.2.3. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Prion Disease Treatment Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Type
- 6.3.1.2.2. By Drug
- 6.3.2. Canada Prion Disease Treatment Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Type
- 6.3.2.2.2. By Drug
- 6.3.3. Mexico Prion Disease Treatment Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Type
- 6.3.3.2.2. By Drug
7. Europe Prion Disease Treatment Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Drug
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Prion Disease Treatment Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Type
- 7.3.1.2.2. By Drug
- 7.3.2. United Kingdom Prion Disease Treatment Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Type
- 7.3.2.2.2. By Drug
- 7.3.3. Italy Prion Disease Treatment Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Type
- 7.3.3.2.2. By Drug
- 7.3.4. France Prion Disease Treatment Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Type
- 7.3.4.2.2. By Drug
- 7.3.5. Spain Prion Disease Treatment Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Type
- 7.3.5.2.2. By Drug
8. Asia-Pacific Prion Disease Treatment Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Drug
- 8.2.3. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Prion Disease Treatment Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Type
- 8.3.1.2.2. By Drug
- 8.3.2. India Prion Disease Treatment Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Type
- 8.3.2.2.2. By Drug
- 8.3.3. Japan Prion Disease Treatment Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Type
- 8.3.3.2.2. By Drug
- 8.3.4. South Korea Prion Disease Treatment Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Type
- 8.3.4.2.2. By Drug
- 8.3.5. Australia Prion Disease Treatment Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Type
- 8.3.5.2.2. By Drug
9. South America Prion Disease Treatment Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Drug
- 9.2.3. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Prion Disease Treatment Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Type
- 9.3.1.2.2. By Drug
- 9.3.2. Argentina Prion Disease Treatment Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Type
- 9.3.2.2.2. By Drug
- 9.3.3. Colombia Prion Disease Treatment Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Type
- 9.3.3.2.2. By Drug
10. Middle East and Africa Prion Disease Treatment Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Drug
- 10.2.3. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Prion Disease Treatment Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Type
- 10.3.1.2.2. By Drug
- 10.3.2. Saudi Arabia Prion Disease Treatment Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Type
- 10.3.2.2.2. By Drug
- 10.3.3. UAE Prion Disease Treatment Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Type
- 10.3.3.2.2. By Drug
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Prion Disease Treatment Market: SWOT Analysis
14. Competitive Landscape
- 14.1. Fresenius SE & Co. KGaA
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
- 14.2. Elite Pharmaceuticals Inc
- 14.3. Ionis Pharmaceuticals Inc
- 14.4. Novartis AG
- 14.5. Merck KGaA
- 14.6. AstraZeneca PLC
- 14.7. Bristol-Myers Squibb Company
- 14.8. Cipla Ltd
- 14.9. Teva Pharmaceuticals
- 14.10. Abbott Laboratories
15. Strategic Recommendations
16. About Us & Disclaimer
